PACVS vs POTS: symptoms, biomarkers, trials and researchliterature-only comparison
A data-driven comparison of Post-Acute COVID-19 Vaccination Syndrome (PACVS) and Postural Orthostatic Tachycardia Syndrome (POTS) built from the Open Source Medicine Foundation biomarker atlases, PubMed literature feeds, ClinicalTrials.gov registry extract and post-acute infection syndrome (PAIS) cohort database.
Post-vaccination syndrome cohorts frequently report new-onset tachycardia and orthostatic intolerance, and some PACVS case series centre on POTS. Both have small evidence bases.
No biomarker atlas exists for POTS, so the biomarker sections below are limited to the other condition. This page compares literature, trials, therapeutics and cohorts.
What each condition is
Post-Acute COVID-19 Vaccination Syndrome
Also known as: PCVS, Post-Vac Syndrome, Post-vaccination syndrome
PACVS (also written PCVS or post-vac syndrome) refers to persistent, Long COVID-like symptoms that begin shortly after SARS-CoV-2 vaccination and last for months in a small subset of recipients. It is not a recognised diagnostic entity in most countries and is defined differently across the handful of registry and survey cohorts that exist (Marburg, Yale LISTEN, VITAE). Research is early-stage: the literature is small, the biomarker evidence comes mainly from case series, and only a few interventional studies are registered.
Atlas scope: Molecular, serologic, immunologic, and functional alterations reported in Post-Acute COVID-19 Vaccination Syndrome (PACVS) — persistent symptoms following SARS-CoV-2 vaccination — from PACVS/PCVS primary studies and post-vaccination adverse-event literature.
OSMF resources: biomarker atlas · literature feed
Postural Orthostatic Tachycardia Syndrome
Also known as: Postural tachycardia syndrome, Dysautonomia
POTS is a disorder of the autonomic nervous system defined by a sustained heart-rate rise of at least 30 beats per minute (40 in adolescents) within ten minutes of standing, without orthostatic hypotension, together with chronic orthostatic symptoms. It is a diagnosis made by tilt-table or active-stand testing rather than a blood test. POTS commonly follows infection, including COVID-19, and overlaps heavily with ME/CFS and Long COVID; OSMF tracks it through a literature feed and clinical-trial registry rather than a dedicated biomarker atlas.
OSMF resources: literature feed
Side-by-side summary
| Measure | PACVS | POTS |
|---|---|---|
| Biomarkers catalogued | 32 | No atlas |
| Biomarker categories covered | autoimmune (8), functional (8), spike (4), molecular (4), metabolic (3), serologic (2), inflammatory (2), proteomic (1) | — |
| Markers with LOINC codes | 3 | — |
| Literature studies tracked | 15 | 75 |
| Most recent tracked study | 24 Sep 2026 | 09 Jul 2026 |
| Registered trials (all statuses) | 2 | 88 |
| Recruiting / not yet recruiting | 2 | 30 |
| Active, not recruiting | 0 | 13 |
| Completed | 0 | 33 |
| Terminated / withdrawn / suspended | 0 | 7 |
| Unknown status | 0 | 5 |
| Named cohorts in PAIS database | 4 | 0 |
| Therapeutic agents tracked | 7 | 128 |
Trial condition matching: PACVS uses keyword matching on registry condition and title fields; POTS uses keyword matching on registry condition and title fields. Trials listing both conditions: 0.
Biomarkers catalogued for PACVS
POTS has no OSMF biomarker atlas, so no shared-marker matching is possible. The PACVS atlas lists 32 markers; the 15 most relevant to this comparison are shown (autonomic, immune, inflammatory and vascular categories first).
- IL-6 Increased inflammatory
- IL-8 Increased inflammatory
- Heart rate variability (HRV) Decreased functional
- Salivary nitric oxide Decreased functional
- Orthostatic heart rate increment Increased functional
- 6-minute walk distance Decreased functional
- Exertional SpO₂ nadir Decreased functional
- Chester Step Test (VO₂ proxy) Decreased functional
- PAC-19QoL score Decreased functional
- Neurofilament light chain (NfL) Increased functional
- S1 in CD16+ monocytes Increased spike
- Circulating spike (post-mRNA myocarditis) Increased spike
- Spike in cutaneous lesions Increased spike
- Spike in neurological tissue Increased spike
- Anti-Spike (Anti-S) antibodies Increased serologic
Overlapping therapeutics under investigation (2)
Agents that appear in registered trials or the OSMF therapeutic-agent database for both PACVS and POTS. Inclusion means an agent is being studied, not that it works.
- Intravenous Immunoglobulin (IVIG)
- N-Acetylcysteine (NAC)
Research cohorts
PACVS cohorts (4)
- Post-Vac-Syndrom Deutschland patient survey survey, n=777, biobank not_applicable
- VITAE vaccine-injury survey (Halma & Varon) survey, n=706, biobank not_applicable
- Yale LISTEN post-vaccination syndrome cohort (Krumholz) survey, n=241, biobank active
- PACVS registry cohort (Semmler/Mundorf) cross sectional, n=191, biobank unknown
POTS cohorts (0)
No named cohort for this condition in the PAIS database yet.
Recent research
Latest PACVS studies
Latest POTS studies
Frequently asked questions
Can you have both PACVS and POTS?
Yes. POTS is a syndrome diagnosed on clinical criteria and can be diagnosed in someone who also has PACVS; 0 registered trials in the OSMF registry list both conditions, and they share 2 therapeutic agents under investigation.
How do the biomarker profiles differ?
OSMF does not maintain a biomarker atlas for POTS, which is diagnosed by physiological or clinical criteria rather than a laboratory panel, so this is a literature-level comparison. PACVS has 32 catalogued markers across 8 categories (most often autoimmune, functional, spike).
Which has more active clinical trials?
POTS has more: 43 active or recruiting trials versus 2 for PACVS (registry snapshot 07 Oct 2026). Totals including completed, terminated and unknown-status studies are 2 for PACVS and 88 for POTS. Condition matching for PACVS, POTS relies on keyword matching of registry condition fields and may miss trials. Trial counts measure research attention, not treatment efficacy.
Which condition has more recent research?
OSMF tracks 15 recent PubMed-indexed studies for PACVS (latest 24 Sep 2026) and 75 for POTS (latest 09 Jul 2026). The feeds hold a rolling window of recent publications, so they indicate current publication pace rather than lifetime output. See the PACVS feed and the POTS feed for the full lists.
Are the same treatments being studied for both?
2 agents appear in the trial registry or therapeutic-agent database for both conditions, including Intravenous Immunoglobulin (IVIG), N-Acetylcysteine (NAC). All of these are investigational for these indications; none is an approved treatment for either condition. Overlap usually reflects shared hypotheses (immune modulation, autonomic support, antiviral or anti-inflammatory strategies) rather than demonstrated efficacy.
Which has larger research cohorts?
The PAIS cohort database lists 4 named cohorts for PACVS and 0 named cohorts for POTS, the largest being Post-Vac-Syndrom Deutschland patient survey (777 enrolled). Cohorts with stored biospecimens and open external access are the most useful for cross-condition biomarker validation.
Related comparisons
Cite this page
@misc{osmf_pacvs_vs_pots,
author = {Open Source Medicine Foundation},
title = {PACVS vs POTS: symptoms, biomarkers, trials and research compared},
year = {2026},
howpublished = {\url{https://research.opensourcemed.info/compare/pacvs-vs-pots.html}},
note = {Data as of 2026-10-07}
}Get OSMF research updates
New biomarker, trial and cohort data, summarised for patients and researchers.
Last updated 07 Oct 2026 (page build). Underlying data: literature feeds 07 Oct 2026 / 10 Jul 2026; trial registry 07 Oct 2026; atlases 30 Jun 2026 / n/a. Generated by scripts/build_compare_pages.py.